Fig. 5

AR-KO LNCaP resist Enza in vivo. a Experimental scheme for in vivo Enza treatment (also see METHODS). Top: scheme for experiments using AR-30 LNCaP clones, in which animals were castrated 3 days before the start of Enza treatment (30 mg/kg/week, i.p). Bottom: scheme for experiments in which KO-16 cells were implanted in castrated NSG mice and Enza treatment was commenced 30 days thereafter. Both experiments were terminated on day 30 since the start of Enza treatment (i.e., day 60 since the tumor cell implantations). b, c Growth curves (by measuring tumor volumes) showing that AR⁺ LNCaP clones were sensitive (b) whereas AR-KO clones were resistant (c) to Enza. In b, *P < 0.01 (Student’s t-test; note that starting from the 4 time point, i.e., day 15, there was only one tumor remaining (see d) and therefore statistics could not be performed). d, e Endpoint tumor images showing that AR⁺ LNCaP cells are sensitive (d) whereas AR-KO cells are refractory (e) to Enza treatment in vivo. Also shown are tumor weight, incidence and P values (determined using unpaired Student’s t-test and χ² test for tumor weight and incidence, respectively)